NRx Pharmaceuticals, Inc. (NRXP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, is gearing up to disclose its financial achievements for the fourth quarter and the entire year ...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE ...

NRx Pharmaceuticals (NRXP)’ wholly-owned subsidiary Hope Therapeutics signed a Stock Purchase Agreement with Smith & Sauer as the first step in a $27.0M financing to fund the planned acquisition ...

NRX invested $27 million in its subsidiary HOPE therapeutics to fund a nationwide rollup of Interventional Psychiatry Clinics. The agreement includes an immediate $2 million investment with a ...

NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute. The stock rose Thursday to $2.92, reaching a six-month high.

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics. NRX shares are trading higher on Thursday after the company announced a ...

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a Delaware-based pharmaceutical company with a market capitalization of $61.63 million, announced the immediate resignation of Janet Rehnquist from its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life ...